Joseph G Wettstein
Overview
Explore the profile of Joseph G Wettstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
2214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harmeier A, Obermueller S, Meyer C, Revel F, Buchy D, Chaboz S, et al.
Eur Neuropsychopharmacol
. 2015 Sep;
25(11):2049-61.
PMID: 26372541
Trace amine-associated receptor 1 (TAAR1) activation by selective endogenous agonists modulates dopaminergic neurotransmission. This results in antipsychotic-like behavior in vivo which might be initiated by an interaction of TAAR1 and...
2.
3.
Kantak K, Wettstein J
Handb Exp Pharmacol
. 2015 May;
228:451-9.
PMID: 25977093
The wide-ranging field of cognition enhancing research along with its ethics as it stands today is summarized. In the forefront are potentially novel drugs and non-pharmacological treatments for cognitive impairment...
4.
Bruns A, Mueggler T, Kunnecke B, Risterucci C, Prinssen E, Wettstein J, et al.
Neuroimage
. 2015 Mar;
112:70-85.
PMID: 25724758
Pharmacological magnetic resonance imaging (phMRI) of the brain has become a widely used tool in both preclinical and clinical drug research. One of its challenges is to condense the observed...
5.
Lindemann L, Porter R, Scharf S, Kuennecke B, Bruns A, von Kienlin M, et al.
J Pharmacol Exp Ther
. 2015 Feb;
353(1):213-33.
PMID: 25665805
Major depressive disorder (MDD) is a serious public health burden and a leading cause of disability. Its pharmacotherapy is currently limited to modulators of monoamine neurotransmitters and second-generation antipsychotics. Recently,...
6.
Jaeschke G, Kolczewski S, Spooren W, Vieira E, Bitter-Stoll N, Boissin P, et al.
J Med Chem
. 2015 Jan;
58(3):1358-71.
PMID: 25565255
Negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu5) have potential for the treatment of psychiatric diseases including depression, fragile X syndrome (FXS), anxiety, obsessive-compulsive disorders, and levodopa induced...
7.
Scharf S, Jaeschke G, Wettstein J, Lindemann L
Curr Opin Pharmacol
. 2014 Dec;
20:124-34.
PMID: 25488569
Fragile X syndrome (FXS) is the most common monogenic form of inherited mental retardation caused by a trinucleotid repeat expansion and transcriptional shutdown of the FMR1 gene. FXS patients present...
8.
Wagner K, Hartmann J, Labermaier C, Hausl A, Zhao G, Harbich D, et al.
Neuropsychopharmacology
. 2014 Nov;
40(5):1222-33.
PMID: 25409593
Stress-induced psychiatric disorders, such as depression, have recently been linked to changes in glutamate transmission in the central nervous system. Glutamate signaling is mediated by a range of receptors, including...
9.
Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef E, Ostland M, et al.
JAMA Psychiatry
. 2014 Apr;
71(6):637-46.
PMID: 24696094
Importance: In schizophrenia, the severity of negative symptoms is a key predictor of long-term disability. Deficient signaling through the N-methyl-D-aspartate receptor is hypothesized to underlie many signs and symptoms associated...
10.
Jagannath A, Butler R, Godinho S, Couch Y, Brown L, Vasudevan S, et al.
Cell
. 2013 Sep;
154(5):1100-1111.
PMID: 23993098
Retinal photoreceptors entrain the circadian system to the solar day. This photic resetting involves cAMP response element binding protein (CREB)-mediated upregulation of Per genes within individual cells of the suprachiasmatic...